Palleon’s lead program, E-602, is a first-in-class enzyme-Fc fusion from Palleon’s EAGLE platform.
E-602 is designed to reinvigorate exhausted T cells in refractory cancer patients by enzymatically degrading T cell surface sialoglycans. These structures contribute to T cell exhaustion by inhibiting immune-activating receptors such as CD28. E-602 also contributes to anti-tumor immunity by desialylating tumor cell surfaces, overcoming Siglec-mediated immunosuppression of innate immune cells, particularly macrophages and dendritic cells.
Palleon plans to file an Investigational New Drug application for E-602 with the U.S. FDA in 2021.